COVID-19 Testing
Conditions
Brief summary
This study tests an adaptation of the HIV Continuum of Prevention, Care, and Treatment Framework (CoPCT) for use in tracking COVID-19 testing and follow-up in a medically and socially vulnerable population. This study uses an integrated research collaborative framework that facilitates dialogue among researchers, community members, and service providers as a tool for optimizing the adaptive intervention and will take place at the North Jersey Community Research Initiative (NJCRI)
Detailed description
This study will use the Multiphase Optimization Strategy (MOST) to optimize an adaptive intervention that successfully navigates COVID-19 medically or socially vulnerable people through a continuum of prevention, care and treatment (CoPCT) modeled on the HIV CoPCT. The COVID-19 CoPCT starts with testing and continues with successful adherence to prevention or treatment guidelines to help prevent and/or treat COVID-19. The study will assess the effectiveness of Navigation Services compared to referrals in increasing COVID-19 testing and Brief Counseling in increasing adherence to the State of NJ recommendations for COVID-19 prevention and treatment. The study will also examine the effect of Critical Dialogue on testing behavior among people who decline to be tested for COVID-19. The investigators will develop decision rules about what evidence-based-interventions work best for what types of people (e.g., those who test right away, versus decliners) and in what period of the COVID-19 continuum. Finally, the study will shed light on factors associated with testing and adherence to NJ recommendations. Investigators will follow Community Based Participatory Research principles in implementing a sequential, multiple assignment randomized trial (SMART) design. Adjusting for possible 15% loss to follow-up, a total sample of 670 people who are medically and socially vulnerable to infection and poor outcomes with COVID-19 will be enrolled as the intent-to treat-sample. The investigators are confident that they can recruit this sample in Essex County, NJ based on their previous experience and because the parent study research team has established relationships with other service agencies in the community from which, in addition to NJCRI, research participants will be drawn. The primary outcome is completion of the COVID-19 test within one week of the first intervention session The study will include 3 stages in which participants will be randomized to one of two possible interventions as follows: 1. Eligible and consenting participants will be randomized to receive the first-stage intervention: Navigation Services (NS) or standard services (referral to testing and NJ digital information brochure after testing). The primary outcome is completion of the COVID-19 test within one week of the intervention session. 2. Those who get tested will be randomized to receive the second-stage intervention: continue with NS or standard treatment or switch to Brief Counseling (BC). The outcome will be adherence to NJ recommendations. For those testing positive, adherence means engaging in a 14-day quarantine, receiving medical care as needed and contact tracing. For those testing negative, adherence means social distancing and wearing masks. 3. Those who do not get tested will be randomized into their second-stage intervention to continue with NS or digital brochure or switch to Critical Dialogue (CD). The outcome will be completing COVID-19 testing within 1 week of the second stage intervention session. Those who complete the testing will then be randomized to either continue with NS or digital brochure or switch to BC. Those who do not get tested will be randomized to continued NS or digital brochure or switch to CD. The outcome will be adherence to NJ recommendations, as defined above. All variables will be measured using standardized measures selected from the National Institutes of Health (NIH) PhenX Toolkit. For the primary aim of comparing effects of Navigation Services versus referral on testing behavior and NJ recommendations adherence, using standard sample size formula for difference of two proportions, a total sample size of 582 subjects is needed to have 80% power at α=0.05 to detect a 10% difference in proportions, assuming 70% in the referral group will complete testing and adhere to specific NJ recommendations. The 582 sample size has 85% to detect a difference of 15% in adherence rates to NJ recommendations between two interventions.
Interventions
Navigation services include assessment and support with service referrals. Each participant will meet with a peer navigator in person or on Zoom Conferencing for 30 minutes to go over results from their social and health needs assessment that is retrieved from the baseline assessment. The navigator shares information about COVID-19, answers questions about testing, and makes referrals to other needed services
Critical Dialogue includes three one-hour-long, open-group-sessions facilitated in person or online by a trained licensed facilitator. Group critical dialogue is prompted by thematic images developed by the NCCB to foster a deeper understanding of how systematic stigma, feelings of rage as victims of discrimination, and/or apathy may impact participants' beliefs and behaviors related to COVID-19 and empower participants to make critical choices to protect their health and the health of their communities.
Brief Counseling is a 15-minute post-COVID-19 test session delivered by a trained licensed clinician in person or via Zoom Conferencing. In the session, the clinician shares the test results and offers recommendations and information about COVID-19 treatment and prevention.
Referral will consist of a five-minute phone call where an outreach worker offers participants information about COVID-19 testing and encourages them to get tested within one week. A digital brochure containing NJ recommendations is e-mailed or texted to participants.
Sponsors
Study design
Intervention model description
SMART Design
Eligibility
Inclusion criteria
* over 18 years of age * having high risk to contract COVID or develop related complications * able to speak English * able and willing to provide informed consent.
Exclusion criteria
* under 18 years of age * not at high risk to contract COVID or develop related complications * unable to speak English * unable and unwilling to provide informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Stage 1: Completion of COVID-19 Test After First Randomization | Stage 1: Within one week of completing baseline. | For the first stage intervention, the primary outcome is coming to the agency and completing the COVID-19 antigen test one week after completing the baseline. |
| Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post Baseline | Stage 2: 6 months post baseline (4th follow up visit) | For the second stage intervention, the primary outcome is self-reported completion of COVID-19 test in the past 30 days at the follow up completed 6 months after baseline. Study participants were asked whether they had completed a COVID-19 test in the past 30 days. |
Countries
United States
Participant flow
Recruitment details
Participants were recruited into the study at the North Jersey Community Research Initiative (NJCRI), one of New Jersey's largest and most comprehensive HIV/AIDS community-based organization.
Participants by arm
| Arm | Count |
|---|---|
| Navigation (1)+ Navigation (2) Participants in this group were randomized in Stage 1 to receive Navigation Services and randomized to receive Navigation Services in Stage 2.
Navigation Services: Navigation services include assessment and support with service referrals. Each participant will meet with a peer navigator in person or on Zoom Conferencing for 30 minutes to go over results from their social and health needs assessment that is retrieved from the baseline assessment. The navigator shares information about COVID-19, answers questions about testing, and makes referrals to other needed services | 160 |
| Navigation (1) + Brief Counseling (2) Participants in this Group were randomized to receive Navigation services in Stage 1 and randomized to receive Brief Counseling in Stage 2.
Brief Counseling: Brief Counseling is a 15-minute post-COVID-19 test session delivered by a trained licensed clinician in person or via Zoom Conferencing. In the session, the clinician shares the test results and offers recommendations and information about COVID-19 treatment and prevention. | 36 |
| Navigation (1) + Critical Dialogue (2) Participants in this group were randomized to receive Navigation Services in Stage 1 and randomized to receive Critical Dialogue in Stage 2.
Critical Dialogue: Critical Dialogue includes three one-hour-long, open-group-sessions facilitated in person or online by a trained licensed facilitator. Group critical dialogue is prompted by thematic images developed by the NCCB to foster a deeper understanding of how systematic stigma, feelings of rage as victims of discrimination, and/or apathy may impact participants' beliefs and behaviors related to COVID-19 and empower participants to make critical choices to protect their health and the health of their communities | 126 |
| Brochure (1) + Brochure (2) Participants in this group were randomized in stage 1 to receive a digital brochure and randomized to receive a digital brochure in Stage 2.
Referral and Digital Brochure: Referral will consist of a five-minute phone call where an outreach worker offers participants information about COVID-19 testing and encourages them to get tested within one week. A digital brochure containing NJ recommendations is e-mailed or texted to participants. | 165 |
| Brochure (1)+ Brief Counseling (2) Participants in this group were randomized in Stage 1 to receive a Brochure and were randomized to receive Brief Counseling in Stage 2.
Brief Counseling: Brief Counseling is a 15-minute post-COVID-19 test session delivered by a trained licensed clinician in person or via Zoom Conferencing. In the session, the clinician shares the test results and offers recommendations and information about COVID-19 treatment and prevention. | 32 |
| Brochure (1) + Critical Dialogue (2) Participants in this group were randomized to receive Navigation Services in Stage 1 and were randomized to receive Critical Dialogue in Stage 2.
Critical Dialogue: Critical Dialogue includes three one-hour-long, open-group-sessions facilitated in person or online by a trained licensed facilitator. Group critical dialogue is prompted by thematic images developed by the NCCB to foster a deeper understanding of how systematic stigma, feelings of rage as victims of discrimination, and/or apathy may impact participants' beliefs and behaviors related to COVID-19 and empower participants to make critical choices to protect their health and the health of their communities. | 137 |
| Total | 656 |
Baseline characteristics
| Characteristic | Navigation (1) + Brief Counseling (2) | Navigation (1) + Critical Dialogue (2) | Brochure (1) + Brochure (2) | Brochure (1)+ Brief Counseling (2) | Brochure (1) + Critical Dialogue (2) | Navigation (1)+ Navigation (2) | Total |
|---|---|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 2 Participants | 4 Participants | 6 Participants | 2 Participants | 5 Participants | 7 Participants | 26 Participants |
| Age, Categorical Between 18 and 65 years | 34 Participants | 122 Participants | 159 Participants | 30 Participants | 132 Participants | 153 Participants | 630 Participants |
| COVID tested within previous 30 days | 12 Participants | 26 Participants | 40 Participants | 8 Participants | 39 Participants | 40 Participants | 165 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 4 Participants | 17 Participants | 25 Participants | 4 Participants | 24 Participants | 22 Participants | 96 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 30 Participants | 105 Participants | 133 Participants | 23 Participants | 105 Participants | 133 Participants | 529 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 2 Participants | 4 Participants | 7 Participants | 5 Participants | 8 Participants | 5 Participants | 31 Participants |
| Race/Ethnicity, Customized American Indian or Alaskan Native | 0 Participants | 7 Participants | 7 Participants | 1 Participants | 8 Participants | 10 Participants | 33 Participants |
| Race/Ethnicity, Customized Asian | 0 Participants | 6 Participants | 3 Participants | 0 Participants | 0 Participants | 0 Participants | 9 Participants |
| Race/Ethnicity, Customized Black or African American | 31 Participants | 99 Participants | 127 Participants | 26 Participants | 99 Participants | 127 Participants | 509 Participants |
| Race/Ethnicity, Customized Missing/Not Reported | 0 Participants | 0 Participants | 1 Participants | 2 Participants | 2 Participants | 1 Participants | 6 Participants |
| Race/Ethnicity, Customized Native Hawaiian or Pacific Islander | 0 Participants | 2 Participants | 2 Participants | 0 Participants | 4 Participants | 1 Participants | 9 Participants |
| Race/Ethnicity, Customized Other or Unknown | 2 Participants | 7 Participants | 16 Participants | 2 Participants | 14 Participants | 14 Participants | 55 Participants |
| Race/Ethnicity, Customized White | 3 Participants | 12 Participants | 16 Participants | 2 Participants | 12 Participants | 19 Participants | 64 Participants |
| Region of Enrollment United States | 36 participants | 126 participants | 165 participants | 32 participants | 137 participants | 160 participants | 656 participants |
| Sex/Gender, Customized Female | 10 Participants | 53 Participants | 67 Participants | 12 Participants | 57 Participants | 72 Participants | 271 Participants |
| Sex/Gender, Customized Gender Missing/Unknown | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 2 Participants |
| Sex/Gender, Customized Male | 25 Participants | 68 Participants | 90 Participants | 19 Participants | 76 Participants | 86 Participants | 364 Participants |
| Sex/Gender, Customized none of these describe me (includes those identifying as non-binary, transgender, and bi-gender) | 1 Participants | 5 Participants | 7 Participants | 0 Participants | 4 Participants | 2 Participants | 19 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk |
|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 328 | 0 / 160 | 0 / 36 | 0 / 126 | 0 / 340 | 0 / 165 | 0 / 32 | 0 / 137 |
| other Total, other adverse events | 0 / 328 | 0 / 160 | 0 / 36 | 0 / 126 | 0 / 340 | 0 / 165 | 0 / 32 | 0 / 137 |
| serious Total, serious adverse events | 0 / 328 | 0 / 160 | 0 / 36 | 0 / 126 | 0 / 340 | 0 / 165 | 0 / 32 | 0 / 137 |
Outcome results
Stage 1: Completion of COVID-19 Test After First Randomization
For the first stage intervention, the primary outcome is coming to the agency and completing the COVID-19 antigen test one week after completing the baseline.
Time frame: Stage 1: Within one week of completing baseline.
Population: Population for Stage 1
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Navigation (1) | Stage 1: Completion of COVID-19 Test After First Randomization | Stage 1 COVID tested | 78 participants |
| Navigation (1) | Stage 1: Completion of COVID-19 Test After First Randomization | Missing/Unknown | 0 participants |
| Brochure Only | Stage 1: Completion of COVID-19 Test After First Randomization | Stage 1 COVID tested | 71 participants |
| Brochure Only | Stage 1: Completion of COVID-19 Test After First Randomization | Missing/Unknown | 0 participants |
Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post Baseline
For the second stage intervention, the primary outcome is self-reported completion of COVID-19 test in the past 30 days at the follow up completed 6 months after baseline. Study participants were asked whether they had completed a COVID-19 test in the past 30 days.
Time frame: Stage 2: 6 months post baseline (4th follow up visit)
Population: Population includes baseline at Stage 2.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Navigation (1) | Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post Baseline | Missing | 0 participants |
| Navigation (1) | Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post Baseline | Reported COVID tested in prior 30 days | 40 participants |
| Brochure Only | Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post Baseline | Missing | 18 participants |
| Brochure Only | Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post Baseline | Reported COVID tested in prior 30 days | 12 participants |
| Navigation (1) + Critical Dialogue (2) | Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post Baseline | Reported COVID tested in prior 30 days | 26 participants |
| Navigation (1) + Critical Dialogue (2) | Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post Baseline | Missing | 57 participants |
| Brochure (1) + Brochure (2) | Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post Baseline | Reported COVID tested in prior 30 days | 40 participants |
| Brochure (1) + Brochure (2) | Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post Baseline | Missing | 78 participants |
| Brochure (1)+ Brief Counseling (2) | Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post Baseline | Reported COVID tested in prior 30 days | 8 participants |
| Brochure (1)+ Brief Counseling (2) | Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post Baseline | Missing | 16 participants |
| Brochure (1) + Critical Dialogue (2) | Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post Baseline | Missing | 53 participants |
| Brochure (1) + Critical Dialogue (2) | Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post Baseline | Reported COVID tested in prior 30 days | 39 participants |